In one paragraphArticle in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Elena SindramInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. elena.sindram@uniklinik-freiburg.de.ORCID 0000-0002-5700-7364 Juan Eduardo Montero-HernándezLaboratory of Molecular Basis of Altered Immune Homeostasis Inserm UMR 1163, Institut Imagine, Paris, France.ORCID 0000-0003-1158-6978 Quentin FrengerInserm UMR S 1109 - Immuno-Rheumatologie Moléculaire, University of Strasbourg, Strasbourg, France.ORCID 0000-0002-2057-3813 Hannah van DijkInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Anna LangInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Vanessa ZeidlerInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0009-0004-6548-5712 Rebecca MarsiskeInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0009-0006-5870-5080 Manuel RhielInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0003-0741-2780 Kerstin GeigerInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Tatjana I CornuInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-7206-7541 Emily M MaceDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Frédéric GrosInserm UMR S 1109 - Immuno-Rheumatologie Moléculaire, University of Strasbourg, Strasbourg, France.ORCID 0000-0002-6252-4323 Bodo GrimbacherInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-6897-6806 Fernando E SepulvedaLaboratory of Molecular Basis of Altered Immune Homeostasis Inserm UMR 1163, Institut Imagine, Paris, France.ORCID 0000-0001-5865-4929 Yolanda R CarrascoDepartment of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid, Spain.ORCID 0000-0003-2148-1926 Virginia AndreaniInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. virginia.andreani@uniklinik-freiburg.de.ORCID 0000-0002-8991-038X Laura Gámez-DíazInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. laura.gamez@uniklinik-freiburg.de.ORCID 0000-0002-6800-9736 Funding
Agence Nationale de la Recherche (ANR) ANR-18-CE15-0017Agence Nationale de la Recherche (ANR) ANR-22-CD17-0048Agence Nationale de la Recherche (ANR) ANR-23-CE17-0022Deutsche Forschungsgemeinschaft (DFG) 2021/B3-FolDeutsche Forschungsgemeinschaft (DFG) 450392965Deutsche Forschungsgemeinschaft (DFG) CIBSS-EXC-2189 ID 390939984Deutsche Forschungsgemeinschaft (DFG) EXC 2155 Project ID 390874280Deutsche Forschungsgemeinschaft (DFG) EXC-2189 Project ID 390939984Deutsche Forschungsgemeinschaft (DFG) GR 1617/17-1 519635399Deutsche Forschungsgemeinschaft (DFG) ID 403222702Deutsche Forschungsgemeinschaft (DFG) ID GR1617/8-1Deutsche Forschungsgemeinschaft (DFG) SFB1160/3 B5EUCOR-Seed the Money Grant ACTIvGerman Federal Ministry of Education and Research GAIN 01GM2206AGerman Federal Ministry of Research, Technology and Space CCR5 FKZ 01EK2205MCIN/AEI/10.13039/501100011033/ FEDER, UE PID2021-125831OB-I00Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2023.115.1
6 · The paper itselfAbstract
Patients with lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency typically suffer from severe B cell dysfunction. However, the underlying mechanisms remain incompletely understood. In this study, we identify non-muscle myosin IIA (NMIIA) as an interaction partner of LRBA in B cells, and uncover a role for LRBA in regulating actin cytoskeleton dynamics during B cell activation. LRBA-deficient B cells exhibit abnormal migration, impaired F-actin polymerization, and reduced B cell receptor signalling and polarization upon activation. In addition, LRBA deficiency severely disrupts immune synapse formation as evidenced by diminished central SMAC formation, reduced microtubule organizing center translocation and disrupted BCR and lysosome polarization. Consistent with these defects, internalization of the BCR-antigen complex is also impaired. Mechanistically, NMIIA activation, assessed by myosin light chain (MLC) phosphorylation, is reduced in LRBA-deficient cells. In addition, LRBA co-localizes with active NMIIA during both migration and immune synapse formation. Collectively, our findings establish LRBA as an important regulator of cytoskeleton dynamics during B cell activation, which may contribute to the defective humoral immunity observed in LRBA-deficient patients.
Indexed as
Actin CytoskeletonAdaptor Proteins, Signal TransducingB-LymphocytesNonmuscle Myosin Type IIAActinsAnimalsCell MovementHumansImmunological SynapsesLymphocyte ActivationMicePhosphorylationProtein BindingReceptors, Antigen, B-CellSignal TransductionActinsAdaptor Proteins, Signal TransducingNonmuscle Myosin Type IIAReceptors, Antigen, B-Cell
Identifiers
PMID42286213
PMCPMC13400755
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390